+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Lupus Nephritis Epidemiology Forecast 2025-2034

  • PDF Icon

    Report

  • 150 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102544
Approximately 40% of patients with systemic lupus erythematosus are affected by lupus nephritis, according to a research article published in the International Journal of Molecular Sciences (2024). Lupus nephritis epidemiology forecast indicates that the condition is more common in women, with the prevalence significantly higher in women in their 30s and 40s. Various studies suggest that the male-to-female ratio of lupus nephritis is about 1:5.

Lupus Nephritis Epidemiology Forecast Report Coverage

The “Lupus Nephritis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of lupus nephritis. It projects the future incidence and prevalence rates of lupus nephritis cases across various populations. The study covers age, gender, and type as major determinants of the lupus nephritis population. The report highlights patterns in the prevalence of lupus nephritis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on lupus nephritis epidemiology in the 8 major markets.

Regions Covered

  • The United States
  • Germany
  • France
  • Italy
  • Spain
  • The United Kingdom
  • Japan
  • India

Lupus Nephritis Understanding: Disease Overview

Lupus nephritis is a serious kidney complication of systemic lupus erythematosus. In this condition, the immune system targets the kidneys, which often leads to inflammation and damage to the structures involved in filtering waste from the blood.

Common symptoms of lupus nephritis include swelling in the legs, feet, or face, high blood pressure, dark or foamy urine, and weight gain due to fluid retention. Some people may not experience noticeable symptoms until significant kidney damage has occurred. Based on the extent and pattern of kidney involvement, lupus nephritis is classified into six types, with Class III (focal) and Class IV (diffuse) considered the severe forms.

Lupus Nephritis Epidemiology Perspective

The lupus nephritis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for lupus nephritis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for lupus nephritis and their trends. The lupus nephritis detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
  • Around 40% of patients with systemic lupus erythematosus are affected by lupus nephritis, as per a research article published in the International Journal of Molecular Sciences (2024). Moreover, it is reported that lupus nephritis is the most prevalent form of secondary glomerulonephritis.
  • The prognosis of lupus nephritis remains unpredictable despite advancements in treatment, with an estimated 10% to 30% of patients progressing to end-stage renal disease (ESRD) within the first 10 years of the disease, according to a 2021 study published in the Rheumatic Disease Clinics of North America.
  • Various studies reveal that a greater prevalence rate of lupus nephritis is documented among people of African, Hispanic, and Asian descent compared to Caucasians.

Age-Based Lupus Nephritis Epidemiology Insights

As per a study published in Pediatric Nephrology (2023), lupus nephritis generally develops early in the disease course, occurring most commonly in women aged 20 to 40 years. Further, it is observed that children with systemic lupus erythematosus are prone to renal involvement compared to adults.

Gender-Based Lupus Nephritis Epidemiology Insights

Systemic lupus erythematosus (SLE) is estimated to have a higher prevalence in women than men, with the female-to-male ratio estimated to be 9:1, according to a case-based narrative review published in the journal Kidney Medicine (2024). Similarly, it is reported that lupus nephritis, a severe manifestation of SLE, is more prevalent in women. Various studies suggest that the male-to-female ratio of lupus nephritis is about 1:5.

Country-wise Lupus Nephritis Epidemiology Segment

The lupus nephritis epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of lupus nephritis varies between countries, owing to differences in factors such as genetics, environmental exposures, healthcare access, diagnostic practices, and the prevalence of systemic lupus erythematosus, among others. The incidence and severity of lupus nephritis are significantly influenced by genetic predispositions, particularly within specific ethnic groups. A population-based study published in Arthritis & Rheumatology (2023) on the epidemiology of lupus nephritis in the United States found that the average annual incidence of lupus nephritis was 1 per 100,000 individuals, with the male-to-female ratio estimated to be 1:3.

Lupus Nephritis: Treatment Overview

The initial treatment for lupus nephritis usually includes corticosteroids, such as prednisone, to manage inflammation. High doses are given to the patient in the beginning, followed by a gradual taper. In addition to corticosteroids, immunosuppressive lupus nephritis therapeutics like mycophenolate mofetil (CellCept) or azathioprine (Imuran) are commonly prescribed to suppress the immune system. Cyclophosphamide (Cytoxan) is typically given in more severe cases, particularly Class IV. Newer biologic therapies (rituximab and belimumab) may also be recommended to lupus nephritis patients who do not respond to traditional treatments.

Key Questions Answered

  • What are the key findings of lupus nephritis epidemiology in the 8 major markets?
  • What will be the total number of patients with lupus nephritis across the 8 major markets during the forecast period?
  • What was the country-wise lupus nephritis epidemiology scenario in the 8 major markets in the historical period?
  • Which country will have the highest number of lupus nephritis patients during the forecast period of 2025-2034?
  • Which key factors would influence the shift in the patient population of lupus nephritis during the forecast period of 2025-2034?
  • What are the currently available treatments in the lupus nephritis market?
  • What are the disease risks, signs, symptoms, and unmet needs of lupus nephritis?

Scope of the Lupus Nephritis Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of lupus nephritis based on several factors.
  • Lupus Nephritis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The lupus nephritis report helps to identify the patient population and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Lupus Nephritis Market Overview - 8 MM
3.1 Lupus Nephritis Market Historical Value (2018-2024)
3.2 Lupus Nephritis Market Forecast Value (2025-2034)
4 Lupus Nephritis Epidemiology Overview - 8 MM
4.1 Lupus Nephritis Epidemiology Scenario (2018-2024)
4.2 Lupus Nephritis Epidemiology Forecast (2025-2034)
5 Disease Overview
5.1 Signs and Symptoms
5.2 Causes
5.3 Risk Factors
5.4 Guidelines and Stages
5.5 Pathophysiology
5.6 Screening and Diagnosis
5.7 Types of Lupus Nephritis
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
7 Epidemiology Scenario and Forecast - 8 MM (218-2034)
7.1 Key Findings
7.2 Assumptions and Rationale
7.3 Diagnosed Prevalent Cases of Lupus Nephritis
7.4 Gender-Specific Cases of Lupus Nephritis
7.5 Age-Specific Cases of Lupus Nephritis
8 Epidemiology Scenario and Forecast: United States (218-2034)
8.1 Assumptions and Rationale in the United States
8.2 Diagnosed Prevalent Cases of Lupus Nephritis in the United States
8.3 Gender-Specific Cases of Lupus Nephritis in the United States
8.4 Age-Specific Cases of Lupus Nephritis in the United States
9 Epidemiology Scenario and Forecast: United Kingdom (218-2034)
9.1 Assumptions and Rationale in the United Kingdom
9.2 Diagnosed Prevalent Cases of Lupus Nephritis in the United Kingdom
9.3 Gender-Specific Cases of Lupus Nephritis in the United Kingdom
9.4 Age-Specific Cases of Lupus Nephritis in the United Kingdom
10 Epidemiology Scenario and Forecast: Germany (218-2034)
10.1 Assumptions and Rationale in Germany
10.2 Diagnosed Prevalent Cases of Lupus Nephritis in Germany
10.3 Gender-Specific Cases of Lupus Nephritis in Germany
10.4 Age-Specific Cases of Lupus Nephritis in Germany
11 Epidemiology Scenario and Forecast: France (218-2034)
11.1 Assumptions and Rationale in France
11.2 Diagnosed Prevalent Cases of Lupus Nephritis in France
11.3 Gender-Specific Cases of Lupus Nephritis in France
11.4 Age-Specific Cases of Lupus Nephritis in France
12 Epidemiology Scenario and Forecast: Italy (218-2034)
12.1 Assumptions and Rationale in Italy
12.2 Diagnosed Prevalent Cases of Lupus Nephritis in Italy
12.3 Gender-Specific Cases of Lupus Nephritis in Italy
12.4 Age-Specific Cases of Lupus Nephritis in Italy
13 Epidemiology Scenario and Forecast: Spain (218-2034)
13.1 Assumptions and Rationale in Spain
13.2 Diagnosed Prevalent Cases of Lupus Nephritis in Spain
13.3 Gender-Specific Cases of Lupus Nephritis in Spain
13.4 Age-Specific Cases of Lupus Nephritis in Spain
14 Epidemiology Scenario and Forecast: Japan (218-2034)
14.1 Assumptions and Rationale in Japan
14.2 Diagnosed Prevalent Cases of Lupus Nephritis in Japan
14.3 Gender-Specific Cases of Lupus Nephritis in Japan
14.4 Age-Specific Cases of Lupus Nephritis in Japan
15 Epidemiology Scenario and Forecast: India (218-2034)
15.1 Assumptions and Rationale in India
15.2 Diagnosed Prevalent Cases of Lupus Nephritis in India
15.3 Gender-Specific Cases of Lupus Nephritis in India
15.4 Age-Specific Cases of Lupus Nephritis in India
16 Patient Journey17 Treatment Challenges and Unmet Needs18 Key Opinion Leaders (KOL) Insights